ConductScience.org, home

Paper40918151

CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms.

Liu H and 9 others. Open Med (Wars), 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms. Papers, record 40918151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40918151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CircASH1L-mediated tumor progression in triple-negative breast cancer: PI3K/AKT pathway mechanisms.
PubMed
Journal
Open Med (Wars)
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-09-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu HHaiyan
2Wu JJiaming
3Gong JJin
4Zhu JJing
5Liu JJie
6Chen XXiaoqing
7Qu SShaohua
8Chen JJintao
9Zhou ZZhisheng
10Fan XXulong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124729100Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.Apoptosis2014https://conductscience.org/library/papers/24729100PubMed
231690584LncRNA-mediated regulation of SOX9 expression in basal subtype breast cancer cells.RNA2020https://conductscience.org/library/papers/31690584PubMed
337415164Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.Mol Cancer2023https://conductscience.org/library/papers/37415164PubMed
437968332Non-coding RNAs in disease: from mechanisms to therapeutics.Nat Rev Genet2024https://conductscience.org/library/papers/37968332PubMed
537792593Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment.Radiographics2023https://conductscience.org/library/papers/37792593PubMed
639107323Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells.Sci Rep2024https://conductscience.org/library/papers/39107323PubMed
738799250Role of ICAM-1 in triple-negative breast cancer.Open Med (Wars)2024https://conductscience.org/library/papers/38799250PubMed
832264877The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.Mol Cancer2020https://conductscience.org/library/papers/32264877PubMed
938065194Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.Lancet2024https://conductscience.org/library/papers/38065194PubMed
1038029538A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer.Cancer Lett2024https://conductscience.org/library/papers/38029538PubMed
1137660039Advances in immunotherapy for triple-negative breast cancer.Mol Cancer2023https://conductscience.org/library/papers/37660039PubMed
1238651302Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.Histopathology2024https://conductscience.org/library/papers/38651302PubMed
1333481008circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.J Biochem2021https://conductscience.org/library/papers/33481008PubMed
1438859856circBRAF promotes the progression of triple-negative breast cancer through modulating methylation by recruiting KDM4B to histone H3K9me3 and IGF2BP3 to mRNA.Am J Cancer Res2024https://conductscience.org/library/papers/38859856PubMed
1532192494Noncoding RNAs in gastric cancer: implications for drug resistance.Mol Cancer2020https://conductscience.org/library/papers/32192494PubMed
1636176752Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer.Cancer Drug Resist2022https://conductscience.org/library/papers/36176752PubMed
1732976598Coexistence of two quadruplex-duplex hybrids in the PIM1 gene.Nucleic Acids Res2020https://conductscience.org/library/papers/32976598PubMed
1831054369Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis.Biomaterials2019https://conductscience.org/library/papers/31054369PubMed
1932893525Roles of miRNA and lncRNA in triple-negative breast cancer.J Zhejiang Univ Sci B2020https://conductscience.org/library/papers/32893525PubMed
2035580441Eriodictyol inhibits breast carcinogenesis by targeting circ_0007503 and repressing PI3K/Akt pathway.Phytomedicine2022https://conductscience.org/library/papers/35580441PubMed

See all 28 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40918151

GET https://conductscience.org/api/papers/v1/40918151/references?page=2